CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise...
ENCINITAS, Calif., Sept. 27, 2024 /PRNewswire/ -- Cliffside Family Dentistry is now offering 3D printing technology to improve the accuracy...
Axtria's GenAI innovations were recognized at India's most prestigious AI awards for driving operational excellence and transforming solutions for life...
RADNOR, Pa., Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services...
ST. LOUIS, Sept. 27, 2024 /PRNewswire/ -- Mercy's industry-leading work in data and artificial intelligence has placed Byron Yount, PhD, chief...
VIENNA, Va., Sept. 27, 2024 /PRNewswire/ -- Alpha Omega, a leader in mission-focused technology solutions, proudly announces that we have been awarded...
VERONA, Wis., Sept. 27, 2024 /PRNewswire/ -- Epic and our customers protect the privacy of many Americans' health data. At...
Pelvic health startup Hyivy Health poised to offer better solutions to the 300M patients with pelvic floor dysfunction causing chronic...
WASHINGTON, DC / ACCESSWIRE / September 27, 2024 / On September 17th, World Patient Safety Day (WPSD), the Biden-Harris Administration...
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27,...
Compassion Center Austin introduces Texans to natural pain management and opioid risk reduction through the Texas Compassionate Use Program (TCUP)....
WARSAW, POLAND / ACCESSWIRE / September 27, 2024 / Humaneva Inc. has entered into a significant investment agreement with Viking...
Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic painMIAMI, FL / ACCESSWIRE / September 27, 2024...
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a...
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company...
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical...
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine)...
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly...
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM,...
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and...